Abstract
TDD with programmable intrathecal drug delivery systems (IDDS) has been approved for chronic malignant and nonmalignant pain treatment since 1991 and severe spasticity since 1992. Early clinical IDDS studies specified an “abdominal pocket” as the pump implant location, resulting in this as the defined on-label location. Alternate pump pocket locations are preferred by some implanting physicians for patient-specific reasons, but full evaluation of the risks and benefits of these alternate pump sites has not been performed. Presented here is an evaluation of real-world registry data on the potential risks and benefits of 7415 pump implants.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Paper Title
Journal
Date
